ValuEngine Downgrades Myriad Genetics (MYGN) to Buy
Myriad Genetics (NASDAQ:MYGN) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.
A number of other brokerages also recently weighed in on MYGN. Barclays downgraded Myriad Genetics from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $38.00 to $30.00 in a report on Wednesday, September 5th. BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 29th. Zacks Investment Research downgraded Myriad Genetics from a “buy” rating to a “sell” rating in a report on Monday, August 27th. Bank of America increased their price target on Myriad Genetics from $31.00 to $34.00 and gave the stock a “sell” rating in a report on Wednesday, August 22nd. Finally, Stephens increased their price target on Myriad Genetics from $45.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 22nd. Four analysts have rated the stock with a sell rating, four have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $37.82.
Myriad Genetics stock traded up $0.97 during trading hours on Wednesday, reaching $47.06. 502,500 shares of the company’s stock were exchanged, compared to its average volume of 741,966. The company has a current ratio of 3.19, a quick ratio of 2.86 and a debt-to-equity ratio of 0.01. Myriad Genetics has a twelve month low of $27.23 and a twelve month high of $50.44. The company has a market cap of $3.24 billion, a P/E ratio of 39.22, a PEG ratio of 3.20 and a beta of 0.43.
In other Myriad Genetics news, VP Richard M. Marsh sold 70,672 shares of Myriad Genetics stock in a transaction that occurred on Wednesday, July 11th. The shares were sold at an average price of $42.88, for a total transaction of $3,030,415.36. Following the transaction, the vice president now owns 154,869 shares of the company’s stock, valued at approximately $6,640,782.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Richard M. Marsh sold 33,000 shares of Myriad Genetics stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $40.00, for a total transaction of $1,320,000.00. Following the transaction, the vice president now directly owns 157,197 shares in the company, valued at approximately $6,287,880. The disclosure for this sale can be found here. In the last three months, insiders have sold 273,672 shares of company stock worth $11,299,415. Insiders own 6.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Hartford Investment Management Co. bought a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $276,000. State of Wisconsin Investment Board lifted its position in shares of Myriad Genetics by 4.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 66,800 shares of the company’s stock worth $2,496,000 after buying an additional 3,000 shares in the last quarter. UBS Group AG lifted its position in shares of Myriad Genetics by 265.1% during the 1st quarter. UBS Group AG now owns 146,336 shares of the company’s stock worth $4,324,000 after buying an additional 106,258 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $906,000. Finally, Swiss National Bank lifted its position in shares of Myriad Genetics by 2.6% during the 2nd quarter. Swiss National Bank now owns 121,600 shares of the company’s stock worth $4,544,000 after buying an additional 3,100 shares in the last quarter.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Article: Fiduciary
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.